Insider Buying: Retension Pharmaceuticals (NASDAQ:RTSN) Director Purchases $120,000.00 in Stock

Retension Pharmaceuticals, Inc. (NASDAQ:RTSN) Director Franklin Berger purchased 10,000 shares of Retension Pharmaceuticals stock in a transaction on Tuesday, October 13th. The shares were acquired at an average cost of $12.00 per share, for a total transaction of $120,000.00. Following the purchase, the director owned 10,000 shares in the company, valued at approximately $120,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Retension Pharmaceuticals Stock Performance

Shares of RTSN stock traded up $0.31 during mid-day trading on Tuesday, hitting $11.63. 137,519 shares of the company’s stock were exchanged, compared to its average volume of 157,559. Retension Pharmaceuticals, Inc. has a fifty-two week low of $9.66 and a fifty-two week high of $12.50.

Retension Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.